Laboratory for Cardiovascular Theranostics
Laboratory for Cardiovascular Theranostics
Azucena Rendón Ángel
Role of Cellular Senescence in Myocardial Infarction.
Following myocardial infarction (MI) senescent cells accumulate into cardiac tissue. They contribute to MI-associated dysfunction via pro-oxidant phenotype and secretion of senescent-associated proteins (SASP). MI activate aging pathways in the heart that are distinct from canonical senescent profile, resulting in a stress-sensitive cardiomyocytes, also in ischemia remote zone, promoting apoptosis. Novel or combination anti-aging approaches may be required to improve outcomes in MI patients. Although much is known about apoptosis following MI in young animals, little is known about the aging-induced apoptotic pathways in the heart after MI.
Extracellular Vesicles as Therapeutic Target for Cardioprotective Approach.
Extracellular vesicles are important cellular effectors that can mediate different effects. Both the cellular target and the molecular content of exosomes depend on the producer cell. Understanding the nature of vesicles and the mechanisms through which they act may lead to develop new strategies to treat heart disease.
Extracellular Vesicles as Biomarkers
Secreted extracellular vesicles (EV) such as exosomes and microvesicles, are prominent and universal form of intercellular communication process. All cells in the organism secrete EV, which are taken up by surrounding cells or circulate in the blood and eventually are taken up by cells at a distance. EV transport and deliver bioactive molecules such as proteins and nucleic acids, which activate intracellular signalling pathways and regulate functions of recipient cells by exerting autocrine, paracrine, and endocrine effects. EV released by cells into the circulation and body fluids display different RNA and protein contents in healthy subjects and patients with different diseases, which can be measured as potential biomarkers of disease. We have number of ongoing studies to evaluate the diagnostic performance of EV surface proteins as biomarkers in various disease conditions, including cancer, degenerative neurological and cardiovascular diseases.
Swiss National Science Foundation – SINERGIA-SNF
GRANT_NUMBER: CRSII5_202302 Targeting cellular senescence in physiological, pathological and iatrogenic conditions
Swiss National Science Foundation – SNF
GRANT_NUMBER: IZCOZ0_18294 EXaCT: EXosomes based Combination Therapy to target multiple signaling within cardioprotective pathways
EUROPEAN COMMISSION – Horizon 2020 – Research and Innovation Framework Programme
Evolving reversible iMmunocapture by membrane sensing peptides: towARds scalable extracellular VEsicLes isolation – MARVEL
Granted amount (total): EUR 1’881’104
Collaboration of departments: Laboratory for Cardiovascular Theranostics and Lugano Cell Factory
Consiglio Nazionale delle Ricerche – Italy, Istituto Cardiocentro Ticino – Switzerland, Università Vita-Salute San Raffaele – Italy, Hansabiomed Life Sciences OU – Estonia, Paperdrop Diagnostics – Spain, Amires Sro – Czech Republic.
VELUX STIFTUNG Science-Funding Foundation
Cardiac exosomes for myocardial senescence repair
FONDAZIONE LEONARDO (Lugano, Switzerland)
Exploring mechanism beyond susceptibility of senescent cardiomyocytes to SARS-CoV-2.
A CCT research in the European scientific network against heart attack – The Swiss National Fund has selected a research project bearing the signature of Dr. Lucio Barile of the Laboratory for Cardiovascular Theranostics – Istituto Cardiocentro Ticino. A total of around CHF 300,000 has been allocated to the project.
Our paper on Exosomes and Cardioprotection published on Cardiovascular Research has been voted by senior Editorial Team of the CVR for the “Best Basic Research Paper Award 2018” during the European Society of Cardiology scientific meeting held in Paris in 2019
First meeting regarding our SINERGIA project at EPFL Lausanne
EBiomedicine entrusted an internationally recognized scientists and professor in immunology at University of Pittsburgh Prof. Theresa L. Whiteside to write a commentary on our paper on extracellular vesicles and SARS-CoV-2
The Laboratory for Cardiovascular Theranostics and Lugano Cell Factory (Istituto Cardiocentro Ticino_EOC) joint the 1-year meeting for the EU-project MARVEL that will introduce a breakthrough in current Extracellular Vesicles (EVs) isolation standards. 1-Year after the start of the project we finally had our first in-person meeting.